Lead Product(s) : NOE-115
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Noema Pharma Doses First Patient in Phase 2a Study of NOE-115 for Menopause Symptoms
Details : NOE-115 is a broad-spectrum monoamine modulator, small molecule drug candidate, which is being evaluated for the treatment of women with vasomotor symptoms.
Product Name : NOE-115
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : NOE-115
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : XOMA
Deal Size : $490.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, XOMA has acquired all rights to ebopiprant held by ObsEva, including the Organon/ObsEva license agreement and the IP associated with the asset.
Product Name : OBE022
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
November 22, 2022
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : XOMA
Deal Size : $490.0 million
Deal Type : Acquisition
Lead Product(s) : Merotocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Merotocin (FE-202767 or carba-1-[4-FBzlGly(7)]dOT) is a selective peptidic oxytocin receptor agonist. It is currently in clinical development for the treatment of preterm mothers requiring lactation support.
Product Name : FE 202767
Product Type : Peptide
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Merotocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ebopiprant, when administered with atosiban infusion to women with preterm labor, reduced delivery in singleton pregnancies at 48 hours after the start of dosing by over 50% compared to atosiban alone.
Product Name : OBE022
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Organon
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022)
Details : Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.
Product Name : OBE022
Product Type : Other Small Molecule
Upfront Cash : $500.0 million
July 27, 2021
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Organon
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the PROLONG study, ebopiprant reduced delivery in singleton pregnancies at 48 hours after the start of dosing by 55% compared to atosiban alone. Overall, 12.5% of women receiving ebopiprant delivered within 48 hours of starting treatment compared to p...
Product Name : OBE022
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Ebopiprant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable